Table 2. Lifetime Costs, Health Benefits, and Cost-effectiveness of Risk- and Cholesterol Level–Based Statin Treatment Strategies in a Cohort of 500 000 US Men and 500 000 US Women Aged 40 Years at Baseline.

Policy	Patient-Years of Treatment Eligibility	No. of ASCVD Events	Discounted QALYs	Discounted Costs, 2019 US $	ICER ($/QALY)a
Women
Standard care	8 485 471	354 209	11 582 459	125 046 215 620	Reference
Add AR10 of 5.0%-7.4% and LDL-C level of 160-189 mg/dL	8 698 683	353 782	11 582 673	125 044 868 352	Cost-saving
Add AR10 of 5.0%-7.4% and LDL-C level of 130-159 mg/dL	9 099 545	353 166	11 582 850	125 048 146 932	18 487
Add remainder AR10 ≥5.0%	9 850 750	352 211	11 583 006	125 060 057 499	76 576
Men
Standard care	11 153 224	480 658	10 914 126	90 574 138 606	Reference
Add AR10 of 5.0%-7.4% and LDL-C level of 160-189 mg/dL	11 454 862	479 925	10 915 020	90 562 851 415	Cost-saving
Add AR10 of 5.0%-7.4% and LDL-C level of 130-159 mg/dL	12 105 382	478 761	10 916 180	90 558 695 685	Cost-saving
Add remainder AR10 of ≥5.0%	13 316 940	477 281	10 917 063	90 581 623 102	25 977
Combined women and men
Standard care	19 638 695	834 867	22 496 585	215 620 354 226	Reference
Add AR10 of 5.0%-7.4% and LDL-C level of 160-189 mg/dL	20 153 545	833 707	22 497 693	215 607 719 767	Cost-saving
Add AR10 of 5.0%-7.4% and LDL-C level of 130-159 mg/dL	21 204 927	831 927	22 499 030	215 606 842 617	Cost-saving
Add remainder AR10 of ≥5.0%	23 167 690	829 492	22 500 068	215 641 680 601	33 558

Abbreviations: AR₁₀, 10-year absolute risk for atherosclerotic cardiovascular disease (ASCVD); ICER, incremental cost-effectiveness ratio; LDL-C, low-density lipoprotein cholesterol; QALY, quality-adjusted life-year.

^aIncremental to prior most effective, nondominated strategy.